Amendments to the Research Plan. On an annual basis, or more often as the Parties deem appropriate, the JDC will prepare amendments to each then-current Research Plan for each Collaboration Antigen for approval of the JSC. Each such amended Research Plan will specify the items described in Section 5.2(a)(i). Such amended Research Plan will cover the next calendar year (and additional periods as reasonably determined by the Parties). Such updated and amended Research Plan will reflect any changes, re-prioritization of studies within, reallocation of resources with respect to, or additions to, respectively, the then-current Research Plan. In addition, the JDC may prepare amendments for approval by the JSC to the Research Plan, as appropriate, from time to time during the calendar year in order to reflect changes in such plans or budget for such calendar year, in each case, in accordance with the foregoing. Once approved by the JSC, the amended annual Research Plan will become effective for the applicable period on the date approved by the JSC (or such other date as the JSC will specify). Any JSC-approved amended Research Plan will supersede, respectively, the previous Research Plan for the Collaboration Antigen for the applicable period.
Amendments to the Research Plan. Pfizer shall from time to time, in its sole discretion, discuss with Medarex the research and development of Target Antigens, during the term of this Agreement; provided, however, that Medarex shall not be obligated to agree to work on a Target Antigen proposed by Pfizer or grant any rights or obligations with respect to such Target Antigens or antibodies to them. If Medarex accepts a Target Antigen, the parties shall adopt an amendment to the Research Plan during the ensuing one hundred and eighty (180) day period.
Amendments to the Research Plan. Either Party may, acting through its representatives on the JSC, propose amendments to the Research Plan at any time. The JSC may amend the Research Plan provided such amendments are mutually agreed to by the JSC representatives of each Party (without reference to the tie-breaking provisions of Section 2.2.3 (Disagreement Resolution)) and in no event may the JSC amend the SoLO Criteria or SoD Criteria, unless such amendments are mutually agreed to by the Parties as provided in Section 14.9 (Entire Agreement; Amendments).
Amendments to the Research Plan a. During the term of this Agreement, Pfizer may from time to time, in its sole discretion, propose in writing to Medarex the research and development of one or more target molecules during the term of this Agreement (each, a “Pfizer Proposal”). Each such Pfizer Proposal shall contain the following information with respect to each proposed target molecule: its common name, its amino acid sequence and its GenBank accession number. In addition, each Pfizer Proposal shall indicate the calendar year in which Pfizer desires for Medarex to commence research under the Research Plan with respect to such target molecule.
